The Effects of Centella Asiatica on Diabetic Foot Ulcers

Comparison of the Effectiveness of Centella Asiatica and Placebo on Infection Control and Foot Ulcer Healing in Diabetic Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240913063024N1

Enrollment

Registered

2025-02-01

Start date

2025-01-04

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Diabetic foot ulcer. Condition 2: Diabetic foot ulcer. Type 1 diabetes mellitus with foot ulcer Type 2 diabetes mellitus with foot ulcer

Interventions

Intervention 1: Intervention group: In the treatment group, Centella Asiatica extract capsules will be dispensed in plastic packer bottles. The prescription will be one capsule (Centella Asiatica 475

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diabetic patients (Type 1 and type 2) 18 years old and above

Exclusion criteria

Exclusion criteria: Patients with poor nutritional status ( serum albumin 1.5 mg/dL) Abnormal liver function tests (AST, ALT values >2.5 fold of upper limits of normal)

Design outcomes

Primary

Measure	Time frame
Wound Surface Area Measurement. Timepoint: Wound Surface Area Measurement on Days 0, 7, 14, 21, and 30. Method of measurement: Using a caliper tool, the length and width of the wound are measured, and the area is assessed on days 0, 7, 14, 21, and 30. The wound area is evaluated by measuring both dimensions and calculating the total area. Additionally, a digital photograph will be taken to monitor changes in the wound surface area. The size of the wound will subsequently be analyzed using ImageJ image processing software and compared to the measurements obtained on the first day.;Wound depth measurement. Timepoint: Wound depth Measurement on Days 0, 7, 14, 21, and 30. Method of measurement: A sterile cotton swab is used to measure wound depth. The swab is inserted very slowly, gently, and vertically at the deepest part of the wound, until it reaches its maximum depth. To accurately identify this, it may be necessary to examine multiple areas of the wound.;Wound infection control. Timepoint: In the 1st and 14th days of treatment. Method of measurement: Culture of wound secretions.	—

Measure

Time frame

Wound Surface Area Measurement. Timepoint: Wound Surface Area Measurement on Days 0, 7, 14, 21, and 30. Method of measurement: Using a caliper tool, the length and width of the wound are measured, and the area is assessed on days 0, 7, 14, 21, and 30. The wound area is evaluated by measuring both dimensions and calculating the total area. Additionally, a digital photograph will be taken to monitor changes in the wound surface area. The size of the wound will subsequently be analyzed using ImageJ image processing software and compared to the measurements obtained on the first day.;Wound depth measurement. Timepoint: Wound depth Measurement on Days 0, 7, 14, 21, and 30. Method of measurement: A sterile cotton swab is used to measure wound depth. The swab is inserted very slowly, gently, and vertically at the deepest part of the wound, until it reaches its maximum depth. To accurately identify this, it may be necessary to examine multiple areas of the wound.;Wound infection control. Timepoint: In the 1st and 14th days of treatment. Method of measurement: Culture of wound secretions.

—

Secondary

Measure	Time frame
Blood glucose level. Timepoint: In the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.;Serum levels of inflammatory markers, CRP, and ESR. Timepoint: in the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.;WBC count. Timepoint: In the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.;Fasting blood sugar level. Timepoint: In the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.;HBA1C. Timepoint: In the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.	—

Measure

Time frame

Blood glucose level. Timepoint: In the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.;Serum levels of inflammatory markers, CRP, and ESR. Timepoint: in the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.;WBC count. Timepoint: In the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.;Fasting blood sugar level. Timepoint: In the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.;HBA1C. Timepoint: In the 1st, 14th, and 21st days of treatment. Method of measurement: Blood Tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMomenzadeh Mahmood

Artesh University of Medical Sciences

momenzade@ajaums.ac.ir+98 21 8802 8350

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026